Patents by Inventor Luk E. Vandenberghe

Luk E. Vandenberghe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced AAV-mediated gene transfer for retinal therapies
    Patent number: 10266845
    Abstract: Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: April 23, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Therese Cronin, Jean Bennett, Luk E. Vandenberghe
  • ENHANCED AAV-MEDIATED GENE TRANSFER FOR RETINAL THERAPIES
    Publication number: 20170049910
    Abstract: Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.
    Type: Application
    Filed: August 24, 2016
    Publication date: February 23, 2017
    Inventors: Therese Cronin, Jean Bennett, Luk E. Vandenberghe
  • Enhanced AAV-mediated gene transfer for retinal therapies
    Patent number: 9567376
    Abstract: Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 14, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Therese Cronin, Jean Bennett, Luk E. Vandenberghe
  • ENHANCED AAV-MEDIATED GENE TRANSFER FOR RETINAL THERAPIES
    Publication number: 20150376240
    Abstract: Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.
    Type: Application
    Filed: February 7, 2014
    Publication date: December 31, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Therese Cronin, Jean Bennett, Luk E. Vandenberghe